Combined Anti-Angiogenic and Anti-Inflammatory Nanoformulation for Effective Treatment of Ocular Vascular Diseases
Jianguo Sun,Huiling Nie,Panpan Pan,Qin Jiang,Chang Liu,Min Wang,Yonghui Deng,Biao Yan
DOI: https://doi.org/10.2147/IJN.S387428
IF: 7.033
2023-01-24
International Journal of Nanomedicine
Abstract:Jianguo Sun, 1, &ast Huiling Nie, 2, &ast Panpan Pan, 3, &ast Qin Jiang, 2, &ast Chang Liu, 1 Min Wang, 1 Yonghui Deng, 3, 4 Biao Yan 1 1 Eye Institute and Department of Ophthalmology, Eye & ENT Hospital, State Key Laboratory of Medical Neurobiology, Fudan University, Shanghai, People's Republic of China; 2 The Affiliated Eye Hospital and The Fourth School of Clinical Medicine, Nanjing Medical University, Nanjing, People's Republic of China; 3 Department of Chemistry, Fudan University, Shanghai, People's Republic of China; 4 Department of Gastroenterology and Hepatology, Zhongshan Hospital, Institute of Biomedical Sciences, Fudan University, Shanghai, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yonghui Deng; Biao Yan, Email ; Background: Ocular vascular diseases are the major causes of visual impairment, which are characterized by retinal vascular dysfunction and robust inflammatory responses. Traditional anti-angiogenic or anti-inflammatory drugs still have limitations due to the short-acting effects. To improve the anti-angiogenic or anti-inflammatory efficiency, a dual-drug nanocomposite formulation was proposed for combined anti-angiogenic and anti-inflammatory treatment of ocular vascular diseases. Methods: : (SM) complex nanoformulation was prepared by integrating conbercept (CBC, an anti-angiogenic drug) and MCC950 (MCC, an inhibitor of inflammation) into the surface-modified hollow mesoporous silica nanoparticles (hMSN(SM)). (SM) complex nanoformulation was then characterized by Fourier transform infrared spectroscopy, transmission electron microscopy, zeta potentials, and nitrogen adsorption-desorption measurement. CBC and MCC release profile, cytotoxicity, tissue toxicity, anti-angiogenic effects, and anti-inflammatory effects of (SM) were estimated using the in vitro and in vivo experiments. Results: (SM) complex had no obvious cytotoxicity and tissue toxicity and did not cause a detectable ocular inflammatory responses. (SM) complex was more effective than free CBC or MCC in suppressing endothelial angiogenic effects and inflammatory responses in vitro. A single intraocular injection of (SM) complex potently suppressed diabetes-induced retinal vascular dysfunction, choroidal neovascularization, and inflammatory responses for up to 6 months. Conclusion: : Combined CBC and MCC nanoformulation provides a promising strategy for sustained suppression of pathological angiogenesis and inflammatory responses to improve the treatment outcomes of ocular vascular diseases. Keywords: combined nanocomposite formulation, mesoporous silica nanoparticle, anti-angiogenesis, anti-inflammation, ocular vascular disease Pathological angiogenesis is recognized as the major cause of vision impairment and eventual blindness in the world, including corneal neovascularization, choroidal neovascularization (CNV), and diabetic retinopathy (DR). 1 Pathological factors, such as hyperglycemia, oxidative stress, and hypoxia, can disrupt the normal vasculature and cause vascular dysfunction. 2,3 Vascular dysfunction further leads to the activation of inflammatory cells, contributing to the inflammatory cell filtration and inflammation cascades. 4 Angiogenesis and inflammation is interconnected with each other and pro-inflammatory factors usually have pro-angiogenic effects and vice versa. 5 Pathological angiogenesis and inflammatory responses have been involved in the pathogenesis of ocular vascular diseases. 6 Currently, drug treatments for pathological angiogenesis are mainly dependent on the inhibitors targeting vascular endothelial growth factor (VEGF) signaling, such as bevacizumab, lucentis, aflibercept, and conbercept (CBC). These drugs are often short-acting and required for repetitive intraocular injection to maintain the therapeutic efficiency. 7 However, repetitive injections of anti-VEGF drugs are very expensive and have several side effects on normal vessels, which may lower the patient compliance and cause the poor adherence to anti-VEGF treatment. 8 Anti-inflammatory treatment is achieved by the application of corticosteroids, such as prednisolone and dexamethasone, which are hourly administered by the topical eye drops to inhibit ocular inflammation. 9 However, it is often followed by the gradual decrease of the medication and cessation of therapy due to the rapid elimination and short-acting time. 10 Given the angiogenesis-inflammation interconnection and short-acting effects of current -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology